Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like How a friend’s death turned Colorado teens into anti-overdose activists March 1, 2024 In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domain February 4, 2025 Low-frequency ultrasound influences blood parameters, reserach shows January 22, 2024
In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domain February 4, 2025